Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Sanofi Invests $25 Million in Adagene's SAFEbody Platform for Next-Generation Cancer Immunotherapy
Sanofi has committed up to $25 million in strategic investment to Adagene, extending the biotech's cash runway into 2027 and supporting clinical development of its lead SAFEbody candidate muzastotug.
Regeneron Expands Patent Protection for Aflibercept with New Formulation Patent Against Amgen
Regeneron filed a new patent infringement complaint against Amgen on June 17, 2025, asserting U.S. Patent No. 12,331,099 covering a stable liquid ophthalmic formulation without buffer requirements.
BioNTech to Acquire CureVac for $1.25 Billion to Strengthen mRNA Cancer Immunotherapy Pipeline
BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities.
Commit Biologics Forms Scientific Advisory Board to Advance Complement-Based Cancer and Autoimmune Therapies
Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform.
Regeneron's Trevogrumab Shows Promise in Preserving Muscle Mass When Combined with Wegovy in Weight-Loss Study
Regeneron's experimental drug trevogrumab, when combined with Novo Nordisk's Wegovy (semaglutide), helped preserve up to 80% of lean muscle mass compared to semaglutide alone in a mid-stage clinical study.
Regeneron Licenses Chinese GLP-1/GIP Dual Agonist in $2 Billion Obesity Deal with Hansoh Pharma
Regeneron acquired exclusive rights to HS-20094, a dual GLP-1/GIP receptor agonist from Hansoh Pharmaceuticals, for $80 million upfront and up to $1.93 billion in milestone payments.
BioLineRx Reports Promising Pancreatic Cancer Trial Results with 64% Response Rate for Motixafortide Combination
BioLineRx's CheMo4METPANC Phase 2 pilot study demonstrated a 64% overall response rate and 91% disease control rate in first-line pancreatic cancer patients treated with motixafortide combination therapy.
Itepekimab Shows Mixed Results in Phase 3 COPD Trials, Meeting Primary Endpoint in One of Two Studies
The AERIFY-1 phase 3 trial met its primary endpoint, demonstrating a statistically significant 27% reduction in moderate or severe COPD exacerbations at week 52 in former smokers treated with itepekimab compared to placebo.
Biohaven's Novel ADCs Show Promising Early Clinical Results with TopoIx Payload Technology
Biohaven's Trop2-directed ADC BHV-1510 demonstrated tumor reduction in all six patients when combined with cemiplimab, including confirmed partial responses and activity in brain metastases.
Regeneron Partners with Telesis Bio to Deploy Revolutionary DNA Synthesis Platform for Accelerated Drug Development
Regeneron Pharmaceuticals has entered a licensing agreement with Telesis Bio to deploy the Gibson SOLA platform at its R&D facilities for automated gene synthesis.